Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 9/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 9/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 9/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 9/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9598147 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8334678 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9597689 | 0.92 | GRIN2D (0.84) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9599421 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9598408 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9598395 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9598049 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8906265 | 0.90 | GRIN2D (0.82) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9597701 | 0.90 | GRIN2D (0.82) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9209443 | 0.89 | GRIN2D (0.80) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
| US-10894069-B2 | Topical antiviral formulations and methods of using the same | MCELVANY CHRISTOPHER A (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200230187-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY CHRISTOPHER A (US) | 2020-07-23 | — | — | US | disclosed |
| US-10456435-B2 | Topical antiviral formulations and methods of using the same | MCELVANY, Christopher A. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180207213-A1 | TOPICAL ANTIVIRAL FORMULATIONS AND METHODS OF USING THE SAME | MCELVANY, CHRISTOPHER | 2018-07-26 | — | — | US | disclosed |
| US-8486374-B2 | Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions | FOAMIX LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-11-27 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | GRIN2D 4715/4885GRIN3B 4112/4885GRIN1 3664/4885 |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | SSTR2, SSTR3, LPXN | GRIN2D 4148/4885GRIN3B 4410/4885GRIN1 4335/4885 |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | GRIN2D 4685/4885GRIN3B 4287/4885GRIN1 4141/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | GRIN2D 4685/4885GRIN3B 4287/4885GRIN1 4141/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | GRIN2D 457/4885GRIN3B 172/4885GRIN1 304/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | GRIN2D 7/4885GRIN3B 6/4885GRIN1 4/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | GRIN2D 3109/4885GRIN3B 3088/4885GRIN1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.